Predictors of intravenous amiodarone induced liver injury  by Diab, O.A. et al.
The Egyptian Heart Journal (2016) xxx, xxx–xxxHO ST E D  BY
Egyptian Society of Cardiology
The Egyptian Heart Journal
www.elsevier.com/locate/ehj
www.sciencedirect.comPredictors of intravenous amiodarone induced liver
injury* Corresponding author at: 14, Mostafa Helmy St., Heliopolis,
Cairo, Egypt. Tel.: +20 1090555025; fax: +20 2 24820416.
E-mail addresses: osama.diab.eg@gmail.com (O.A. Diab), johnzarif@
yahoo.com (J. Kamel), dr.mido86@hotmail.com (A.A. Abd-Elhamid).
1 Tel.: +20 1009551311.
2 Tel.: +20 1019953356.
Peer review under responsibility of Egyptian Society of Cardiology.
http://dx.doi.org/10.1016/j.ehj.2016.05.001
1110-2608  2016 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Please cite this article in press as: Diab OA et al. Predictors of intravenous amiodarone induced liver injury, The Egypt Heart J (2016), http://dx.doi.org/10
ehj.2016.05.001O.A. Diab a,*, John Kamel a,1, Ahmed Adel Abd-Elhamid b,2aDepartment of Cardiology, Ain Shams University Hospital, Ain Shams University, Cairo, Egypt
bShobra General Hospital, Cairo, EgyptReceived 28 January 2016; accepted 4 May 2016KEYWORDS
Intravenous amiodarone;
Parenteral amiodarone;
Liver injury;
Drug induced liver injuryAbstract Background: Intravenous (IV) amiodarone may be associated with liver injury that may
necessitate drug discontinuation. The prediction of amiodarone induced liver injury (AILI) and its
severity may help careful patient monitoring or the choice of other measures alternative to amio-
darone in high risk patients. Little is known regarding predictors of AILI.
Objectives: To address the predictors of AILI and its severity.
Methods: The study included 180 patients indicated for IV amiodarone therapy who were divided
into 2 groups: cases (90 patients) who developed AILI, and controls (90 patients) who did not
develop AILI. AILI was deﬁned as aminotransferase (ALT and AST) elevation by P2 folds of
baseline levels. Severe AILI was deﬁned as enzyme elevation by >5 folds of baseline values.
Results: Multivariate analysis showed that the presence of cardiomyopathy (P= 0.032), conges-
tive hepatomegaly (P= 0.001), increasing baseline total bilirubin (P< 0.0001), direct current car-
dioversion (P= 0.015), and increasing dose of amiodarone (P= 0.014) to be independent
predictors for AILI. Regarding severity of AILI, inotropic support (P= 0.034), congestive hep-
atomegaly (P= 0.012), increasing baseline total bilirubin (P= 0.001), and increasing dose of
amiodarone (P= 0.002) were found to be independent predictors for severe AILI. Among cases,
linear regression analysis showed that baseline ALT was the only signiﬁcant independent predictor
of post-amiodarone ALT (P< 0.0001), while baseline AST (P< 0.0001) and EF (P= 0.012) were
the only signiﬁcant independent predictors of post-amiodarone AST.
Conclusions: Compromised cardiac, hepatic, and hemodynamic conditions, with increasing dose of
IV amiodarone were associated with AILI. Severity of liver injury had linear relationship with base-
line aminotransferase levels and left ventricular systolic function.
 2016 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Drug induced liver injury (DILI) due to oral amiodarone was
extensively studied. However, the available data regarding
acute hepatotoxicity form intravenous (IV) amiodarone are
not far beyond case reports.1–16 The mechanisms of liver injury.1016/j.
2 O.A. Diab et al.with IV amiodarone are controversial. Ischemic injury due to
compromised hemodynamic conditions may have a role.5 Sol-
ubilizers in the IV amiodarone preparation such as polysorbate
80 were reported to be responsible for hepatotoxicity, possibly
due to immune-mediated alteration of hepatocellular mem-
brane.6,16 Importantly, the mechanism of injury with IV amio-
darone is different from that in chronic exposure to oral
therapy; therefore, acute hepatic injury following IV amio-
darone does not preclude subsequent oral therapy.6,17
Acute elevation of liver enzymes following IV amio-
darone use ranged from mild asymptomatic to severe life
threatening, and frequently necessitates drug discontinuation.
In most of the reported cases, the liver injury occurred
within 24–48 h of therapy and reversed within 2–3 weeks
of discontinuation.
Parenteral amiodarone is commonly used in critically ill
and hemodynamically unstable intensive care unit patients.
Therefore, multiple factors may predispose patients to IV
amiodarone induced liver injury (AILI). Possible predisposing
factors for AILI were variably reported in different case stud-
ies. Underlying liver injury from heart failure, high dose of IV
amiodarone, hypotension from ventricular arrhythmias (VAs),
and postoperative therapy following coronary artery bypass
grafting (CABG) were observed in case reports.4,8,18,19 Up to
our knowledge, there are no prospective clinical studies that
addressed the predictors of AILI.2. Methods
The study included 180 intensive and coronary care unit
patients who received IV amiodarone therapy. Patients were
divided into 2 groups:
– Cases: Included 90 patients who developed AILI deﬁned as
acute rise in serum aminotransferase levels by at least 2
folds of the baseline levels within 24–48 h of IV amiodarone
therapy.
– Controls: Included 90 patients who did not develop AILI.
Patients with underlying decompensated liver cell failure,
hepatic coma, active hepatitis, patients with >5 fold elevation
of aminotransferases relative to upper limit of normal (ULN),
patients who had acute myocardial infarction (MI) within the
past 3 days, and those who received multiple (>one) direct
current (DC) shocks were not enrolled in the study.
2.1. Clinical assessment
Patients were subjected to history taking and physical exami-
nation emphasizing on risk factors (such as hypertension, dia-
betes mellitus, smoking), signs of underlying liver disease,
heart failure, concomitant drug therapy.
2.2. Laboratory investigations
Before initiation of IV amiodarone therapy, liver function
tests, viral markers, hemoglobin level, serum creatinine, serum
sodium and potassium, INR, and random blood sugar were
measured. Liver function tests and viral markers included
the following:Please cite this article in press as: Diab OA et al. Predictors of intravenous amiodar
ehj.2016.05.001– Aminotransferases: Baseline ALT (alanine aminotrans-
ferase) and AST (aspartate aminotransferase) were mea-
sured using standard reagents by reaction rate assay based
on the conversion of NADH to NAD.20 Upper limit of nor-
mal (ULN) values was 44 IU/L for ALT and 34 IU/L for
AST. Post-amiodarone aminotransferase levels were taken
on the same day, 24, and 48 h following IV amiodarone.
Peak levels were taken as post-treatment values.
– Other liver function tests included serum total and direct
bilirubin (reference levels up to 1.2 and 0.3 mg/dl respec-
tively), serum albumin (reference range 3.5 to 5.5 g/dl),
and INR (international normalized ratio) that was consid-
ered high if >1.5.
– Viral markers: Included hepatitis B virus (HBV) surface
antigen detected by ELISA (enzyme linked immunosorbent
assay), and hepatitis C virus (HCV) antibody detected by
EIA (enzyme immunoassay).
Severity AILI was graded according to rise in aminotrans-
ferase level. Due to inclusion of patients with elevated baseline
aminotransferase levels, the severity grading was classiﬁed
based on changes relative to their baseline value rather than
ULN as follows 21:
– Grade 1: 1.25–2.5 folds of baseline value.
– Grade 2: 2.6–3.5 folds of baseline value.
– Grade 3: 3.6–5 folds of baseline value.
– Grade 4: >5 folds of baseline value.
2.3. Radiologic investigations
Transthoracic echocardiography was done to all patients. Left
ventricular dimensions were measured by M-mode in short
axis parasternal view. Left ventricular ejection fraction (EF)
was calculated by M-mode in case of normal regional wall
motions and by 2D (modiﬁed Simpson’s equation) in the pres-
ence of segmental wall motion abnormalities. Valve assessment
including morphology, motion, transvalvular ﬂow, and valve
regurgitation was done. Structural heart disease was deﬁned
as the presence of dilated chambers, akinetic segments, low
EF (<50%), or any signiﬁcant (more than moderate) valve
lesion. Cardiomyopathy (CM) was deﬁned as dilated left ven-
tricle (LV) with or without low EF.
Abdominal ultrasound was done to assess liver size and
parenchyma, any abdominal ﬂuid collection, or splenomegally.
Congestive hepatomegaly was deﬁned as increased liver size
(with or without splenomegally), attributed to right sided heart
failure or severe tricuspid regurge on echocardiography, with
tender hepatomegaly and hepatojugular reﬂux on physical
examination.
2.4. Amiodarone therapy and in-hospital course
Amiodarone was given by IV loading of 5 mg/kg as a 30 min
IV infusion, followed by infusion of 10 mg/kg/day over 24–
48 h. Indication of therapy was documented by 12-lead surface
electrocardiogram (ECG). The duration, total dose received,
and the need of amiodarone discontinuation were recorded.
Causes of discontinuation included signiﬁcant liver injury
deﬁned as >10 fold rise in aminotransferases relative to
ULN, hemodynamically signiﬁcant bradyarrhythmias, ineffec-one induced liver injury, The Egypt Heart J (2016), http://dx.doi.org/10.1016/j.
Amiodarone Induced Liver Injury 3tiveness (failure to cardiovert arrhythmias), or QTc (corrected
QT interval calculated by Bazett formula) prolongation
>500 ms with or without polymorphic ventricular tachycar-
dia. In-hospital course included cardiac arrest, DC cardiover-
sion, cardiopulmonary resuscitation (CPR) before or after
amiodarone, the need for inotropic/vasopressor support
(including dobutamine, dopamine, adrenaline, or nora-
drenaline), hepatic coma, or death.
2.5. Statistical analysis
Statistical Package for Social Sciences (SPSS, Inc, version 21,
Chicago, IL) was used. D’Agostino–Pearson test was used to
ascertain normality of continuous data distribution. Categori-
cal data were expressed as frequencies, while continuous data
were expressed as mean ± SD or median according to data
distribution. Comparison between categorical variables was
done using Chi square or Fisher’s exact test as appropriate.
Comparison between continuous variables was done using
unpaired t-test or Mann–Whitney test as appropriate. Predic-
tors of AILI and severe (grade 4) AILI were listed in logistic
regression models. Clinically relevant or variables with <0.1
signiﬁcance on univariate analysis were further tested in multi-
variate models with conditional backward method. ROC curve
analysis was used to ﬁnd a cutoff value for continuous vari-
ables found to be signiﬁcant predictors on multivariate analy-
sis. Linear regression analysis was used to ﬁnd predictors of
post-amiodarone aminotransferases. Correlations with post-
amiodarone transaminases were done using Spearman’s rho.
P value was considered signiﬁcant if <0.05.
3. Results
3.1. Baseline characteristics
Baseline characteristics and comparison between cases and
controls are shown in Table 1. All patients had baseline amino-
transferase levels <5 folds of ULN before initiating amio-
darone therapy. None of the studied patients was alcohol
user. Cases had more frequent male gender (P= 0.017),
underlying structural heart disease (predominantly cardiomy-
opathy, P= 0.024), chronic liver disease (predominantly con-
gestive hepatomegaly, P< 0.0001), and +ve viral markers
(predominantly HCV, P= 0.026) than controls. Inotropic
support was more frequent in cases than in controls with bor-
derline signiﬁcance. Baseline AST (P= 0.022), total bilirubin
(P< 0.0001), direct bilirubin (P< 0.0001), and serum crea-
tinine (P = 0.016) were higher, while serum albumin
(P= 0.002) was lower in cases than in controls.
3.2. Amiodarone therapy and in-hospital course
Indications of IV amiodarone therapy varied between atrial
ﬁbrillation (AF), supraventricular tachycardia (SVT), and ven-
tricular arrhythmias (VAs) with no difference between cases
and controls (Table 2). Discontinuation rate was 26.6% for
the whole study population, 52.2% among cases, and 1.1%
among controls. The main cause of discontinuation was liver
enzyme elevation. Among cases, IV amiodarone was initiated
in 16 patients following CPR from cardiac arrest due to
VAs, and all received DC cardioversion, while in controls,Please cite this article in press as: Diab OA et al. Predictors of intravenous amiodar
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DC cardioversion before amiodarone therapy (P= 0.002).
There were no signiﬁcant differences between cases and con-
trols regarding a number of patients who developed hepatic
coma (although more in cases than in controls) and in-
hospital deaths within 48 h of amiodarone therapy.
3.3. Predictors of AILI
Univariate logistic regression analysis with AILI as dependent
variable and each of the variables shown in Table 3 as indepen-
dent variables, showed that male gender, underlying CM, con-
gestive hepatomegaly, +ve viral markers, increasing baseline
total and direct bilirubin, lower serum albumin, increasing ran-
dom blood sugar, CPR, and DC cardioversion were found to
be signiﬁcant predictors of AILI.
On multivariate analysis, male gender, CM, inotropic sup-
port, congestive hepatomegaly, +ve viral markers, baseline
transaminases, total and direct bilirubin, serum albumin, ran-
dom blood sugar, CPR, DC cardioversion, and dose of amio-
darone were listed as independent variables in a logistic
regression model. Backward-conditional method retained the
presence of CM (P= 0.032), congestive hepatomegaly
(P= 0.001), increasing baseline total bilirubin (P< 0.0001),
DC cardioversion (P= 0.015), and increasing dose of amio-
darone (P= 0.014) as independent predictors for AILI.
Continuous variables found to be signiﬁcant predictors for
AILI on multivariate analysis (baseline total bilirubin and dose
of amiodarone) were further tested in a ROC curve. ROC
curve analysis (Fig. 1A) showed that a total bilirubin
>1.3 mg/dl could predict AILI with a sensitivity and speci-
ﬁcity of 64.4% and 77.8% respectively (AUC: 0.72, 95% CI:
0.64–0.79, P< 0.0001). Regarding dose of amiodarone,
ROC curve analysis did not show a signiﬁcant cutoff value
(AUC: 0.54, 95% CI: 0.46–0.63, P= 0.25).
3.4. Predictors of severe AILI
Among patients with AILI (90 patients), grades 1, 2, 3, and 4
liver injury occurred in 0 (0%), 1 (1.1%), 19 (21.1%), and 70
(77.8%) patients (mean grade: 3.76 ± 0.45). In grade 4 AILI,
mean rise of ALT and AST was 8.53 ± 4.33 and 7.67 ± 5.12
folds from baseline respectively.
Among the whole study population, univariate logistic
regression analysis with severe (grade 4) AILI as dependent
variable and each of the variables shown in Table 4 as indepen-
dent variables showed that inotropic support, congestive hep-
atomegaly, increasing baseline total and direct bilirubins,
lower serum albumin, and increasing dose of amiodarone were
found to be signiﬁcant predictors for severe AILI.
On multivariate analysis, inotropic support, congestive hep-
atomegaly, +ve viral markers, total and direct bilirubins,
serum albumin, random blood sugar, DC cardioversion, and
dose of amiodarone were listed as independent variables in a
logistic regression model. Backward-conditional method
retained inotropic support (P= 0.034), congestive hep-
atomegaly (P= 0.012), increasing baseline total bilirubin
(P= 0.001), and increasing dose of amiodarone (P= 0.002)
as independent predictors for severe AILI.
Continuous variables found to be signiﬁcant predictors for
severe AILI on multivariate analysis (baseline total bilirubin
and dose of amiodarone) were further tested in a ROC curve.one induced liver injury, The Egypt Heart J (2016), http://dx.doi.org/10.1016/j.
Table 1 Baseline characteristics and comparison between cases and controls.
All Cases Controls P value
N= 180 N= 90 N= 90
Age (years) 62.78 ± 12.78 63.65 ± 12.3 61.92 ± 13.25 0.36
Sex (M, F) 92, 88 54, 36 38, 52 0.017
Risk factors
DM 107 52 55 0.64
HTN 123 61 62 0.87
Dyslipidemia 55 29 26 0.62
Smoking 65 36 29 0.27
Structural heart disease 90 52 38 0.037
IHD 93 43 50 0.29
RHD 12 5 7 0.55
CM 79 47 32 0.024
AF/ﬂutter 88 41 47 0.37
Statin use 56 26 30 0.52
Warfarin use 23 9 14 0.26
Antimicrobials 133 70 63 0.23
Inotropic support 15 11 4 0.05
Chronic liver disease 93 56 37 0.005
Congestive hepatomegaly 47 36 11 <0.0001
Cirrhotic changes 46 20 26 0.39
Viral markers
+ve/ve 45/135 30/60 15/75 0.01
HBV 2 1 1
HCV 38 24 14 0.026
Both HBV and HCV 5 5 0
EF (%) 45.93 ± 12.39 46.54 ± 13.64 45.33 ± 11 0.51
EF < 40% 54 32 22 0.11
LVEDD (mm) 56.33 ± 9.5 56.2 ± 9.16 56.46 ± 9.88 0.85
LVESD (mm) 41.03 ± 9.88 40.56 ± 9.89 41.5 ± 9.9 0.52
TR
Normal TV 88 42 46
Mild/moderate 69 35 34 0.74
Severe 23 13 10
MVD
Normal MV 43 20 23
Mild/moderate 126 61 65 0.09
Severe 11 9 2
AVD
Normal AV 111 59 52 0.24
Mild/moderate 67 31 36
Severe 2 0 2
Baseline laboratory tests
ALT (IU/L) 29.94 ± 20.04 (median 23) 32.44 ± 21.97 (median 26) 27.44 ± 17.68 (median 21) 0.14
AST (IU/L) 37.61 ± 22.54 (median 30) 40.96 ± 25.31 (median 35.5) 34.26 ± 18.95 (median 28.5) 0.022
Total bilirubin (mg/dl) 1.71 ± 2.16 (median 1.2) 2.27 ± 2.87 (median 1.7) 1.15 ± 0.72 (median 0.9) <0.0001
Direct bilirubin (mg/dl) 0.82 ± 1.67 (median 0.5) 1.15 ± 2.25 (median 0.8) 0.48 ± 0.57 (median 0.3) <0.0001
Albumin (g/dl) 3.15 ± 0.65 3.01 ± 0.7 3.3 ± 0.57 0.002
INR 1.72 ± 1.38 (median 1.35) 1.79 ± 1.02 (median 1.4) 1.64 ± 1.67 (median 1.3) 0.08
Creatinine (mg/dl) 2.33 ± 3.23 (median 1.4) 2.42 ± 2.36 (median 1.7) 2.24 ± 3.93 (median 1.15) 0.016
Na+ (mEq/L) 135.96 ± 9.46 (median 136) 135.02 ± 11.47 (median 135) 136.91 ± 6.82 (median 137) 0.069
K+ (mEq/L) 4.08 ± 0.96 (median 4) 4.03 ± 1.12 (median 3.9) 4.14 ± 0.77 (median 4.1) 0.19
Hb (gm%) 10.27 ± 2.18 10.17 ± 2.28 10.38 ± 2.09 0.52
Random sugar (mg/dl) 210.1 ± 101.73 (median 192.5) 226.93 ± 121.3 (median 207.5) 193.26 ± 74.35 (median 190) 0.15
M: Male, F:Female, DM: Diabetes Mellitus, HTN: Hypertension, IHD: Ischemic heart disease, RHD: Rheumatic heart disease, CM: Car-
diomyopathy, AF: Atrial ﬁbrillation, HSM: Hepatosplenomegaly, HBV: Hepatitis B virus, HCV: Hepatitis C virus, EF: Ejection fraction,
LVEDD: Left ventricular end diastolic diameter, LVESD: Left ventricular end systolic diameter, TR: Tricuspid regurge, MVD: Mitral valve
disease, AVD: Aortic valve disease, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase and Hb: Hemoglobin.
4 O.A. Diab et al.
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Table 2 Comparison between cases and controls regarding amiodarone therapy and in-hospital course.
Cases N= 90 Controls N= 90 P value
Indication
AF 48 50
SVT 21 19 0.93
VAs 21 21
Dose received (mg) 1198.33 ± 368.45 (median 1200) 1116.66 ± 238.08 (median 1200) 0.13
Duration (h) 27.33 ± 15.88 (median 24) 24.28 ± 6.2 (median 24) 0.64
Discontinuation
Elevated liver enzymes 46 0
Bradycardia 1 0 <0.0001
Ineﬀectiveness 0 1
QTc interval prolongation 0 0
Post-amiodarone ALT (IU/L) 199.05 ± 117.5 (median 169.5) 29.63 ± 16.55 (median 25) <0.0001
ALT rise (folds of baseline values) 7.51 ± 4.28 1.16 ± 0.38 <0.0001
Post-amiodarone AST (IU/L) 229.82 ± 102.76 (median 200.5) 39.02 ± 20.5 (median 31.5) <0.0001
AST rise (folds of baseline values) 6.82 ± 4.8 1.2 ± 0.45 <0.0001
Hepatic coma 3 1 0.62
CPR 16 6 0.023
DC shock 16 3 0.002
Death 9 10 0.8
AF: Atrial ﬁbrillation, SVT: Supraventricular tachycardia, VAs: Ventricular Arrhythmias, QTc: Corrected QT interval, ALT: Alanine
aminotransferase, AST: Aspartate aminotransferase, CPR: Cardiopulmonary resuscitation and DC: Direct current.
Table 3 Predictors of amiodarone induced liver injury on univariate and multivariate logistic regression analyses.
Univariate Multivariate
OR 95% CI P value OR 95% CI P value
Male gender 2.05 1.13–3.71 0.018 –
CM 1.98 1.09–3.6 0.025 2.19 1.06–4.49 0.032
Inotropic support 2.99 0.91–9.78 0.07 –
Congestive hepatomegaly 4.78 2.24–10.22 <0.0001 4.24 1.81–9.93 0.001
+ve viral markers 2.5 1.23–5.06 0.011 –
Increasing baseline ALTa 1.01 0.99–1.02 0.09 –
Increasing baseline ASTa 1.01 1–1.02 0.053 –
Increasing baseline T. bilirubinb 2.44 1.62–3.67 <0.0001 2.9 1.8–4.69 <0.0001
Increasing baseline D. bilirubinb 2.86 1.66–4.91 <0.0001 –
Low baseline s. albuminc 2.05 1.27–3.3 0.003 –
Increasing s. creatinineb 1.01 0.92–1.11 0.7 –
Increasing random sugarb 1.003 1–1.7 0.029 –
Low EFd 1.008 0.98–1.03 0.51 –
CPR 3.02 1.12–8.13 0.028 –
DC shock 6.27 1.75–22.3 0.005 5.83 1.4–24.2 0.015
Increasing dose of amiodaronee 1.001 1–1.003 0.087 1.002 1–1.003 0.014
OR: Odds ratio, CI: Conﬁdence interval, CM: Cardiomyopathy, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, T.
bilirubin: Total bilirubin, D. bilirubin: Direct bilirubin, EF: Ejection fraction, CPR: Cardiopulmonary resuscitation and DC: Direct current.
a In increment of 1 IU/L.
b In increment of 1 mg/dl.
c In decrement of 1 g/dl.
d In decrement of 1%.
e In increment of 1 mg.
Amiodarone Induced Liver Injury 5ROC curve analysis (Fig. 1B) showed that a total bilirubin
>1.6 mg/dl can predict severe AILI with a sensitivity and
speciﬁcity of 52.9% and 77.3% respectively (AUC: 0.67,
95% CI: 0.6–0.74, P< 0.0001). Regarding dose of amio-
darone, ROC curve analysis did not show a signiﬁcant cutoff
value (AUC: 0.55, 95% CI: 0.47–0.64, P= 0.2).Please cite this article in press as: Diab OA et al. Predictors of intravenous amiodar
ehj.2016.05.0013.5. Correlations with post-amiodarone aminotransferases
among cases
Among patients with AILI (90 cases), post-amiodarone ALT
and AST were signiﬁcantly correlated with each of baseline
ALT, AST, total bilirubin, direct bilirubin, and EF (Table 5,one induced liver injury, The Egypt Heart J (2016), http://dx.doi.org/10.1016/j.
Figure 1 A: ROC curve showing predictive effect of total bilirubin on amiodarone induced liver injury (AUC 0.72, 95% CI: 0.64–0.79,
P< 0.0001). A value of >1.3 mg/dl was the best cutoff value that is likely associated with amiodarone induced liver injury. B: ROC curve
showing predictive effect of total bilirubin on severe (grade 4) amiodarone induced liver injury (AUC: 0.67, 95% CI: 0.6–0.74,
P< 0.0001). A value of >1.6 mg/dl was the best cutoff value that is likely associated with severe amiodarone induced liver injury.
Table 4 Predictors of severe (grade 4) amiodarone induced liver injury on univariate and multivariate logistic regression analyses.
Univariate Multivariate
OR 95% CI P value OR 95% CI P value
Male gender 1.48 0.81–2.71 0.19 –
CM 1.36 0.74–2.4 0.31 –
Inotropic support 4.94 1.5–16.2 0.008 4.03 1.11–14.6 0.034
Congestive hepatomegaly 3.19 1.6–6.35 0.001 2.69 1.24–5.83 0.012
+ve viral markers 1.95 0.98–3.87 0.054 –
Increasing baseline ALTa 1.01 0.99–1.02 0.24 –
Increasing baseline ASTa 1.006 0.99–1.02 0.41 –
Increasing baseline T. bilirubinb 1.87 1.33–2.64 <0.0001 2.02 1.35–3.006 0.001
Increasing baseline D. bilirubinb 2.03 1.28–3.2 0.002 –
Low baseline s. albuminc 2.12 1.3–3.44 0.002 –
Increasing s. creatinineb 1.03 0.93–1.12 0.52 –
Increasing random sugarb 1.003 1–1.006 0.069 –
Low EFd 1.01 0.98–1.03 0.33 –
CPR 2.06 0.84–5.08 0.11 –
DC shock 2.37 0.9–6.24 0.079 –
Increasing dose of amiodaronee 1.001 1–1.003 0.027 1.002 1.001–1.003 0.002
OR: Odds ratio, CI: Conﬁdence interval, CM: Cardiomyopathy, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, T.
bilirubin: Total bilirubin, D. bilirubin: Direct bilirubin, EF: Ejection fraction, CPR: Cardiopulmonary resuscitation and DC: Direct current.
a In increment of 1 IU/l.
b In increment of 1 mg/dl.
c In decrement of 1 g/dl.
d In decrement of 1%.
e In increment of 1 mg.
6 O.A. Diab et al.Fig. 2). Post-amiodarone AST, but not ALT, was signiﬁcantly
correlated with LVEDD and LVESD.
Stepwise linear regression analysis with post-amiodarone
ALT and AST as dependant outcomes and baseline ALT,
AST, total and direct bilirubins, and EF as independent
variables showed that baseline ALT was the only signiﬁcant
independent predictor of post-amiodarone ALT
(P< 0.0001), while baseline AST (P< 0.0001) and EF
(P= 0.012) were the only signiﬁcant independent predictors
of post-amiodarone AST.Please cite this article in press as: Diab OA et al. Predictors of intravenous amiodar
ehj.2016.05.0014. Discussion
Identifying the predictors of IV amiodarone induced liver
injury (AILI) may help close patient monitoring or the choice
of other measures alternative to amiodarone in high risk
patients. While risk factors of liver injury with oral
amiodarone were previously characterized,22 little is known
regarding IV amiodarone.
In the current study, the presence of CM, congestive
hepatomegaly, increasing baseline total bilirubin, DCone induced liver injury, The Egypt Heart J (2016), http://dx.doi.org/10.1016/j.
Table 5 Variables correlated with post-amiodarone aminotransferases.
Post-amiodarone ALT Post-amiodarone AST
Age
Correlation coeﬃcient* 0.12 0.17
P value 0.25 0.1
Baseline ALT
Correlation coeﬃcient 0.62 0.48
P value <0.0001 <0.0001
Baseline AST
Correlation coeﬃcient 0.41 0.53
P value <0.0001 <0.0001
Baseline T. bilirubin
Correlation coeﬃcient 0.34 0.29
P value 0.001 0.005
Baseline D. bilirubin
Correlation coeﬃcient 0.31 0.29
P value 0.003 0.005
Baseline s. albumin
Correlation coeﬃcient 0.12 0.09
P value 0.23 0.39
S. creatinine
Correlation coeﬃcient 0.05 0.005
P value 0.58 0.96
Random sugar
Correlation coeﬃcient 0.05 0.15
P value 0.64 0.13
Hemoglobin
Correlation coeﬃcient 0.07 0.02
P value 0.49 0.81
EF
Correlation coeﬃcient 0.22 0.36
P value 0.037 <0.0001
LVEDD
Correlation coeﬃcient 0.15 0.28
P value 0.15 0.007
LVESD
Correlation coeﬃcient 0.13 0.24
P value 0.2 0.022
Dose of amiodarone
Correlation coeﬃcient 0.09 0.14
P value 0.35 0.16
ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, T. bilirubin: Total bilirubin, D. bilirubin: Direct bilirubin, EF: Ejection
fraction, LVEDD: Left ventricular end diastolic diameter and LVESD: Left ventricular end systolic diameter.
* All correlations were done using Spearman’s rho.
Amiodarone Induced Liver Injury 7cardioversion, and increasing dose of amiodarone were found
to be independent predictors for AILI on multivariate analysis.
We demonstrated that underlying CM, congestive hep-
atomegaly, and DC cardioversion increased the possibility
(or odds) of having AILI by 2, 4, and 5 folds respectively,
and every 1 mg/dl increase in baseline total bilirubin raised
the possibility of having AILI by about 3 folds. We also
demonstrated that every 1 mg increase in amiodarone dose
raised the odds of having AILI by 1.002 fold (i.e. 1.9 folds with
a dose of 450 mg) which means that the possibility of liver
injury almost doubles with every 12 hours of IV amiodarone
therapy. Similarly, heart failure, congestive liver disease, highPlease cite this article in press as: Diab OA et al. Predictors of intravenous amiodar
ehj.2016.05.001dose of IV amiodarone, and hypotension from ventricular
arrhythmias were observed in patients with AILI among case
reports.4,18,19
Liver injury was found to be severe in the majority (77.8%)
of our cases as well as most of the case reports, indicating that
injury might follow ‘‘all or none” phenomenon. This can also
explain that the predictors of severe AILI in our study were
similar to those of AILI. However, in a retrospective study,
Huang et al.23 reported that liver injury was mild in 92 out
of 101 patients with IV amiodarone induced hepatotoxicity.
Two reasons were likely behind this discrepancy; the ﬁrst is
the difference in deﬁning the severity of liver injury (theyone induced liver injury, The Egypt Heart J (2016), http://dx.doi.org/10.1016/j.
Figure 2 Correlations with post-amiodarone aminotransferases, showing signiﬁcant correlations with each of baseline ALT (A), AST
(B), total bilirubin (C), and ejection fraction (D).
8 O.A. Diab et al.deﬁned severe injury as ALT > 10 folds of ULN in their
study). The second reason is the incomplete amiodarone dos-
ing regimen given in 55.7% of their study population in the
form of either loading without maintenance or maintenance
without loading. Furthermore, the loading dose in their study
was much lower than that recommended by guidelines.
Although they studied a large number of patients, they did
not include baseline liver functions, abdominal ultrasound,
or echocardiographic measures in their analysis. However,
they found that male gender was a risk factor for IV amio-
darone induced hepatotoxicity which was similar to what we
observed on univariate analysis. The same was also reported
with oral amiodarone.24
In the present study, baseline total bilirubin was a highly
signiﬁcant predictor for AILI and severe AILI. A total biliru-
bin >1.3 mg/dl could predict AILI, while a serum level
>1.6 mg could predict severe AILI with low sensitivity butPlease cite this article in press as: Diab OA et al. Predictors of intravenous amiodar
ehj.2016.05.001higher speciﬁcity. In a similar context, total bilirubin was
found to be a signiﬁcant predictor for drug induced liver injury
(DILI) in general, and a cutoff level P1.0 mg/dL was associ-
ated with high risk of acute liver failure.25 High serum biliru-
bin is associated with hepatic decompensation and was solely
found to be a prognostic marker in patients with chronic liver
disease in which aminotransferases may be mildly elevated.26
We observed that baseline ALT and AST were signiﬁcant pre-
dictors for severity of liver injury on linear regression analysis.
High baseline aminotransferases were also associated with
high risk of acute liver failure in patients with DILI.25
We demonstrated that hemodynamic state might predis-
pose liver to AILI. While the presence of cardiomyopathy
and the need for DC cardioversion due to VAs could predict
AILI, the need for inotropic support was associated with
severe AILI. The debate around liver hypoperfusion whether
or not to be the actual cause of injury associated with IVone induced liver injury, The Egypt Heart J (2016), http://dx.doi.org/10.1016/j.
Figure 3 Illustrative summery of our ﬁndings, showing predictors of the occurrence and severity of IV amiodarone induced liver injury
in the present study. Solid arrows indicate multivariate predictors. Dashed arrows indicate univariate predictors. ALT: Alanine
aminotransferase. EF: Ejection fraction.
Amiodarone Induced Liver Injury 9amiodarone5,6,16 demanded a case control study with multi-
variate analysis. Since we found other factors to be indepen-
dently associated with AILI, the link between liver
hypoperfusion and AILI is likely to be a predisposition rather
than a causal relationship.
Underlying cardiac condition was related to AILI in the
present study in two aspects. The presence of CM was a signif-
icant predictor for its occurrence on logistic regression, and the
EF was a signiﬁcant predictor for its severity on linear regres-
sion. This was in accordance with several case studies in which
LV dysfunction was observed.4,7,12,18,19 The same was also
found with oral amiodarone.22 If direct drug toxicity is
assumed, LV dysfunction delays amiodarone elimination by
prolonging the half life of its metabolites, and therefore might
predispose to liver injury.7
We summarized the predictors of AILI and its severity in
Fig. 3 based on our ﬁndings. In high risk patients, we recom-
mend that beneﬁt of IV amiodarone should be weighed against
its possible hazard, especially in non-life threatening condi-
tions such as atrial ﬁbrillation.
5. Conclusions
Parenteral amiodarone induced liver injury (AILI) and its
severity could be predicted by underlying heart disease (car-
diomyopathy, low EF), liver disease (congestive hepatomegaly,
elevated bilirubin and aminotransferases), hemodynamic insta-
bility (DC cardioversion, inotropic support), and increasing
dose of amiodarone.
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